Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Alectinib

    Client Email Product

    Alectinib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    16
    US DMFs Filed

    US DMFs Filed

    4
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    2
    Other Suppliers

    Other Suppliers

    13
    API REF. PRICE (USD / KG)

    0

    API Market Place

    2
    INTERMEDIATES
    11
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    0

    Canada

    Canada

    1
    Australia

    Australia

    1
    South Africa

    South Africa

    1
    Uploaded Dossiers

    Uploaded Dossiers

    1
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    230.00

    Annual Reports

    643.00

    FDF Market Place

    0

    EXCIPIENTS
    114
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    5

    USFDA Exclusivities

    1
    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    36
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer#:~:text=On%20April%2018%2C%202024%2C%20the,by%20an%20FDA%2Dapproved%20test.

    FDA
    19 Apr 2024
    Share Share
    Alecensa approved as 1st adjuvant for ALK+ early lung cancer
    Alecensa approved as 1st adjuvant for ALK+ early lung cancer

    https://www.businesswire.com/news/home/20240418088206/en

    BUSINESSWIRE
    18 Apr 2024
    Share Share
    ESMO: Roche's Alecensa cuts postsurgery lung cancer recurrence
    ESMO: Roche's Alecensa cuts postsurgery lung cancer recurrence

    https://www.fiercepharma.com/pharma/roches-alecensa-staves-lung-cancer-recurrence-en-route-postsurgery-expansion

    Angus Liu FIERCE PHARMA
    21 Oct 2023
    Share Share
    Genentech’s Alecensa Reduces the Risk of Death by an Unprecedented 76%
    Genentech’s Alecensa Reduces the Risk of Death by an Unprecedented 76%

    https://www.businesswire.com/news/home/20231017469678/en

    BUSINESSWIRE
    18 Oct 2023
    Share Share
    Roche claims study success for targeted drug in early lung cancer
    Roche claims study success for targeted drug in early lung cancer

    https://www.biopharmadive.com/news/roche-alecensa-alk-adjuvant-lung-cancer-results/692548/

    Ben Fidler BIOPHARMADIVE
    02 Sep 2023
    Share Share
    Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC
    Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

    https://www.onclive.com/view/alectinib-meets-dfs-end-point-in-alk-early-stage-nsclc

    ONCLIVE
    01 Sep 2023
    Share Share
    Roche's Alecensa stays on top of Xalkori at 5-year mark
    Roche's Alecensa stays on top of Xalkori at 5-year mark

    https://www.fiercepharma.com/pharma/embargoed-til-weds-5-pm-asco-roche-s-alecensa-stays-top-xalkori-long-term-survival-showing

    Carly Helfand FIERCE PHARMA
    13 May 2020
    Share Share
    NICE final guidance backs Pfizer's Lorviqua
    NICE final guidance backs Pfizer's Lorviqua

    http://www.pharmatimes.com/news/nice_final_guidance_backs_pfizers_lorviqua_1340196

    Selina McKee PHARMA TIMES
    13 May 2020
    Share Share
    New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment
    New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment

    https://www.globenewswire.com/news-release/2020/05/07/2029049/0/en/New-data-at-the-ASCO20-Virtual-Scientific-Program-reflects-Roche-s-commitment-to-accelerating-progress-in-cancer-care.html

    GLOBENEWSWIRE
    07 May 2020
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Alecensa 208434 (Alectinib 150 mg)Capsules
    FDA Confirms Paragraph IV Patent Challenge of Alecensa 208434 (Alectinib 150 mg)Capsules

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-alecensa-208434-alectinib-150-mgcapsules-1581763216.pdf

    FDA
    15 Feb 2020
    Share Share
    Roche to present new data from its broad oncology portfolio at the EU Society
    Roche to present new data from its broad oncology portfolio at the EU Society

    https://www.roche.com/media/releases/med-cor-2019-09-23.htm

    ROCHE
    23 Sep 2019
    Share Share
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing

    https://www.fiercebiotech.com/biotech/asco-shrinking-60-lung-cancers-blueprint-s-ret-drug-poised-for-2020-filing

    Amirah Al Idrus FIERCE BIOTECH
    04 Jun 2019
    Share Share
    Soliris (eculizumab) : Chugai Pharmaceutical vs. Alexion Pharmaceuticals
    Soliris (eculizumab) : Chugai Pharmaceutical vs. Alexion Pharmaceuticals

    https://insight.rpxcorp.com/litigation_documents/13143725

    PATENT LITIGATION
    26 Nov 2018
    Share Share
    Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
    Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?

    https://endpts.com/pfizer-racks-up-its-third-cancer-drug-ok-in-2-months-but-is-it-enough-to-replace-regular-price-hikes/

    John Carroll ENDPTS
    02 Nov 2018
    Share Share
    U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
    U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC

    https://www.businesswire.com/news/home/20181102005583/en

    BUSINESSWIRE
    02 Nov 2018
    Share Share
    Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
    Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use

    https://www.fiercepharma.com/marketing/takeda-alk-drug-alunbrig-trounces-pfizer-s-xalkori-bid-for-earlier-use

    Carly Helfand FIERCE PHARMA
    26 Sep 2018
    Share Share
    Chugai Pharma receives Taiwan FDA approval for Alecensa to treat ALK
    Chugai Pharma receives Taiwan FDA approval for Alecensa to treat ALK

    http://www.pharmabiz.com/NewsDetails.aspx?aid=108932&sid=2

    PHARMABIZ
    16 May 2018
    Share Share
    Roche Korea’s Alecensa gets approval as 1st line lung cancer therapy
    Roche Korea’s Alecensa gets approval as 1st line lung cancer therapy

    http://www.koreabiomed.com/news/articleView.html?idxno=3019

    Marian Chu KOREABIOMED
    13 Apr 2018
    Share Share
    NICE no for Roche’s Alecensa
    NICE no for Roche’s Alecensa

    http://www.pharmatimes.com/news/nice_no_for_roches_alecensa_1231330

    Selina McKee PHARMA TIMES
    11 Apr 2018
    Share Share
    Pfizer files third-gen ALK inhibitor for lung cancer
    Pfizer files third-gen ALK inhibitor for lung cancer

    http://www.pmlive.com/pharma_news/pfizer_files_third-gen_alk_inhibitor_for_lung_cancer_1221723

    Phil Taylor PMLIVE
    14 Feb 2018
    Share Share
    EU OKs first-line use of Roche’s lung cancer drug Alecensa
    EU OKs first-line use of Roche’s lung cancer drug Alecensa

    http://www.pharmatimes.com/news/eu_oks_first-line_use_of_roches_lung_cancer_drug_alecensa_1214832

    Selina McKee PHARMA TIMES
    21 Dec 2017
    Share Share
    Roche scores cancer drug approvals in Europe and US
    Roche scores cancer drug approvals in Europe and US

    https://www.roche.com/media/store/releases/med-cor-2017-12-21.htm

    PREE RELEASE
    21 Dec 2017
    Share Share
    Roche’s Alecensa wins wider US approval for lung cancer
    Roche’s Alecensa wins wider US approval for lung cancer

    http://www.pharmatimes.com/news/roches_alecensa_wins_wider_us_approval_for_lung_cancer_1210764

    Selina McKee PHARMA TIMES
    08 Nov 2017
    Share Share
    CHMP recommends EU approval of Roche’s Alecensa as a first-line treatment
    CHMP recommends EU approval of Roche’s Alecensa as a first-line treatment

    https://www.roche.com/media/store/releases/med-cor-2017-10-13.htm

    PRESS RELEASE
    13 Oct 2017
    Share Share
    Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial
    Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial

    http://www.reuters.com/article/us-health-cancer-roche-pfizer-idUSKBN18W1HH

    Deena Beasley REUTERS
    05 Jun 2017
    Share Share
    Roche Registration Limited Alecensa (alectinib) Recommend Its Authorisation in The Europe
    Roche Registration Limited Alecensa (alectinib) Recommend Its Authorisation in The Europe

    https://www.pharmacompass.com/pdf/news/roche-registration-limited-alecensa-alectinib-receives-approval-in-europe-1491976377.pdf

    EMA
    12 Apr 2017
    Share Share
    Roche’s Alecensa beats Pfizer’s Xalkori in lung cancer trial
    Roche’s Alecensa beats Pfizer’s Xalkori in lung cancer trial

    http://www.pharmatimes.com/news/roches_alecensa_beats_pfizers_xalkori_in_lung_cancer_trial_1191110

    Selina McKee PHARMA TIMES
    10 Apr 2017
    Share Share
    Chugai receives Taiwan nod for Alecensa
    Chugai receives Taiwan nod for Alecensa

    http://www.biospectrumasia.com/biospectrum/news/224770/chugai-receives-taiwan-nod-alecensa

    BIOSPECTRUM
    27 Feb 2017
    Share Share
    Novartis' Zykadia scores priority review and breakthrough designation from FDA
    Novartis' Zykadia scores priority review and breakthrough designation from FDA

    http://www.pharmafile.com/news/513398/novartis-zykadia-scores-priority-review-and-breakthrough-designation-fda

    Matt Fellows PHARMAFILE
    24 Feb 2017
    Share Share
    Roche’s lung cancer drug Alecensa wins EU approval
    Roche’s lung cancer drug Alecensa wins EU approval

    http://www.pmlive.com/pharma_news/roches_lung_cancer_drug_alecensa_wins_eu_approval_1187217

    R Clifford PMLIVE
    22 Feb 2017
    Share Share
    EU nod for Roche’s lung cancer drug Alecensa
    EU nod for Roche’s lung cancer drug Alecensa

    http://www.pharmatimes.com/news/eu_nod_for_roches_lung_cancer_drug_alecensa_1187323

    Selina McKee PHARMATIMES
    22 Feb 2017
    Share Share
    Chugai’s Alecensa receives European conditional marketing authorization
    Chugai’s Alecensa receives European conditional marketing authorization

    http://www.pharmabiz.com/NewsDetails.aspx?aid=100496&sid=2

    PHARMABIZ
    21 Feb 2017
    Share Share
    Competition Stalls Roche Margin Growth; Drugmaker Commits to Diabetes Unit
    Competition Stalls Roche Margin Growth; Drugmaker Commits to Diabetes Unit

    http://www.reuters.com/article/us-roche-results-idUSKBN15G3H5

    John Miller REUTER
    02 Feb 2017
    Share Share
    Tecentriq growth offsets Avastin's US decline at Roche
    Tecentriq growth offsets Avastin's US decline at Roche

    http://www.pmlive.com/pharma_news/tecentriq_growth_offsets_avastins_us_decline_at_roche_1185661

    Phil Taylor PMLIVE
    02 Feb 2017
    Share Share
    December CHMP decisions bring year’s total approvals to 81
    December CHMP decisions bring year’s total approvals to 81

    http://www.pharmatimes.com/news/december_chmp_decisions_bring_years_total_approvals_to_81_1183054

    Selina McKee PHARMATIMES
    03 Jan 2017
    Share Share
    Roche say cancer drug Alecensa gets breakthrough therapy designation
    Roche say cancer drug Alecensa gets breakthrough therapy designation

    http://www.reuters.com/article/us-roche-alecensa-idUSKCN1240B1

    S. Koltrowitz REUTERS
    05 Oct 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search